» Articles » PMID: 38067184

The Management of Data for the Banking, Qualification, and Distribution of Induced Pluripotent Stem Cells: Lessons Learned from the European Bank for Induced Pluripotent Stem Cells

Overview
Journal Cells
Publisher MDPI
Date 2023 Dec 9
PMID 38067184
Authors
Affiliations
Soon will be listed here.
Abstract

The European Bank for induced pluripotent Stem Cells (EBiSC) was established in 2014 as a non-profit project for the banking, quality control, and distribution of human iPSC lines for research around the world. EBiSC iPSCs are deposited from diverse laboratories internationally and, hence, a key activity for EBiSC is standardising not only the iPSC lines themselves but also the data associated with them. This includes enabling unique nomenclature for the cells, as well as applying uniformity to the data provided by the cell line generator versus quality control data generated by EBiSC, and providing mechanisms to share personal data in a secure and GDPR-compliant manner. A joint approach implemented by EBiSC and the human pluripotent stem cell registry (hPSCreg) has provided a solution that enabled hPSCreg to improve its registration platform for iPSCs and EBiSC to have a pipeline for the import, standardisation, storage, and management of data associated with EBiSC iPSCs. In this work, we describe the experience of cell line data management for iPSC banking throughout the course of EBiSC's development as a central European banking infrastructure and present a model for how this could be implemented by other iPSC repositories to increase the FAIRness of iPSC research globally.

Citing Articles

Anti-stroke biologics: from recombinant proteins to stem cells and organoids.

Miao Z, Wang Z, Zheng S, Wang S, Miao C Stroke Vasc Neurol. 2024; 9(5):467-480.

PMID: 38286483 PMC: 11732845. DOI: 10.1136/svn-2023-002883.

References
1.
Kurtz A, Mah N, Chen Y, Fuhr A, Kobold S, Seltmann S . Human pluripotent stem cell registry: Operations, role and current directions. Cell Prolif. 2022; 55(8):e13238. PMC: 9357359. DOI: 10.1111/cpr.13238. View

2.
Kim J, Kawase E, Bharti K, Karnieli O, Arakawa Y, Stacey G . Perspectives on the cost of goods for hPSC banks for manufacture of cell therapies. NPJ Regen Med. 2022; 7(1):54. PMC: 9522845. DOI: 10.1038/s41536-022-00242-7. View

3.
Kurtz A, Seltmann S, Bairoch A, Bittner M, Bruce K, Capes-Davis A . A Standard Nomenclature for Referencing and Authentication of Pluripotent Stem Cells. Stem Cell Reports. 2018; 10(1):1-6. PMC: 5768986. DOI: 10.1016/j.stemcr.2017.12.002. View

4.
Sakurai K, Kurtz A, Stacey G, Sheldon M, Fujibuchi W . First Proposal of Minimum Information About a Cellular Assay for Regenerative Medicine. Stem Cells Transl Med. 2016; 5(10):1345-1361. PMC: 5031183. DOI: 10.5966/sctm.2015-0393. View

5.
Wilkinson M, Dumontier M, Aalbersberg I, Appleton G, Axton M, Baak A . The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016; 3:160018. PMC: 4792175. DOI: 10.1038/sdata.2016.18. View